当前位置: 首页 >> 检索结果
5568. Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature.
作者: Yong Zhang.;Fang Zhang.;Lingdi Zhao.;Xiaomin Fu.;Yiman Shang.;Quanli Gao.
来源: BMC Gastroenterol. 2021年21卷1期399页
Colorectal cancer (CRC) is the third most prevalent cancer worldwide and poses a serious challenge for clinicians. Previous studies have shown promising results in patients with Microsatellite Stable microsatellite-stable CRC refractory to chemotherapy upon treating with (Programmed Cell Death Protein 1) PD-1 inhibitor combined with regorafenib. Herein, we report a unique case of a patient for whom the conventional chemotherapy and radiotherapy were ineffective, but showed a prolonged stable disease with third-line treatment with regorafenib and PD-1 inhibitor, sintilimab.
5569. Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study.
作者: Rongrui Liu.;Lianke Liu.;Chuanhua Zhao.;Yuxian Bai.;Yulong Zheng.;Shu Zhang.;Ning Li.;Jianwei Yang.;Qingxia Fan.;Xiuwen Wang.;Shan Zeng.;Yingjun Zhang.;Weihong Zhang.;Yulei Zhuang.;Ning Kang.;Yingzhi Jiang.;Hongmei Sun.;Jianming Xu.
来源: BMC Gastroenterol. 2021年21卷1期398页
Larotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This open-label, phase 1b study is aimed to evaluate the efficacy, safety of larotinib in patients with advanced esophageal squamous cell carcinoma (ESCC) with EGFR overexpression or amplification pretreated with one or more system regimens, and to recommend an appropriate dose for its further study.
5570. HLA Class I Analysis Provides Insight Into the Genetic and Epigenetic Background of Immune Evasion in Colorectal Cancer With High Microsatellite Instability.
作者: Masahito Kawazu.;Toshihide Ueno.;Koichi Saeki.;Nicolas Sax.;Yosuke Togashi.;Takayuki Kanaseki.;Keigo Chida.;Fumishi Kishigami.;Kazuhito Sato.;Shinya Kojima.;Masafumi Otsuka.;Akihito Kawazoe.;Hitomi Nishinakamura.;Maeda Yuka.;Yoko Yamamoto.;Kazuo Yamashita.;Satoshi Inoue.;Tokiyoshi Tanegashima.;Daisuke Matsubara.;Kenta Tane.;Yosuke Tanaka.;Hisae Iinuma.;Yojiro Hashiguchi.;Shoichi Hazama.;Seik-Soon Khor.;Katsushi Tokunaga.;Masahiro Tsuboi.;Toshiro Niki.;Masatoshi Eto.;Kohei Shitara.;Toshihiko Torigoe.;Soichiro Ishihara.;Hiroyuki Aburatani.;Hiroshi Haeno.;Hiroyoshi Nishikawa.;Hiroyuki Mano.
来源: Gastroenterology. 2022年162卷3期799-812页
A detailed understanding of antitumor immunity is essential for optimal cancer immune therapy. Although defective mutations in the B2M and HLA-ABC genes, which encode molecules essential for antigen presentation, have been reported in several studies, the effects of these defects on tumor immunity have not been quantitatively evaluated.
5571. Prolonged Impairment of Short-Chain Fatty Acid and L-Isoleucine Biosynthesis in Gut Microbiome in Patients With COVID-19.
作者: Fen Zhang.;Yating Wan.;Tao Zuo.;Yun Kit Yeoh.;Qin Liu.;Lin Zhang.;Hui Zhan.;Wenqi Lu.;Wenye Xu.;Grace C Y Lui.;Amy Y L Li.;Chun Pan Cheung.;Chun Kwok Wong.;Paul K S Chan.;Francis K L Chan.;Siew C Ng.
来源: Gastroenterology. 2022年162卷2期548-561.e4页
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with altered gut microbiota composition. Phylogenetic groups of gut bacteria involved in the metabolism of short chain fatty acids (SCFAs) were depleted in SARS-CoV-2-infected patients. We aimed to characterize a functional profile of the gut microbiome in patients with COVID-19 before and after disease resolution.
5572. Comparing Colorectal Cancer Screening Outcomes in the International Cancer Screening Network: A Consortium Proposal.
作者: Nereo Segnan.;Evelien Dekker.;V Paul Doria-Rose.;Carlo Senore.;Linda Rabeneck.;Iris Lansdorp-Vogelaar.; .
来源: Gastroenterology. 2022年162卷3期668-674页 5574. Loss of Endothelial TSPAN12 Promotes Fibrostenotic Eosinophilic Esophagitis via Endothelial Cell-Fibroblast Crosstalk.
作者: Tetsuo Shoda.;Ting Wen.;Julie M Caldwell.;Netali Ben-Baruch Morgenstern.;Garrett A Osswald.;Mark Rochman.;Lydia E Mack.;Jennifer M Felton.;J Pablo Abonia.;Nicoleta C Arva.;Dan Atkins.;Peter A Bonis.;Kelley E Capocelli.;Margaret H Collins.;Evan S Dellon.;Gary W Falk.;Nirmala Gonsalves.;Sandeep K Gupta.;Ikuo Hirano.;John Leung.;Paul A Menard-Katcher.;Vincent A Mukkada.;Philip E Putnam.;Amanda K Rudman Spergel.;Jonathan M Spergel.;Joshua B Wechsler.;Guang-Yu Yang.;Seema S Aceves.;Glenn T Furuta.;Marc E Rothenberg.; .
来源: Gastroenterology. 2022年162卷2期439-453页
Eosinophilic esophagitis (EoE) can progress to fibrostenosis by unclear mechanisms. Herein, we investigated gene dysregulation in fibrostenotic EoE, its association with clinical parameters and specific pathways, and the functional consequences.
5575. The liver steatosis severity and lipid characteristics in primary biliary cholangitis.
作者: Yuan Zhang.;Xing Hu.;Jing Chang.;Jie Chen.;Xue Han.;Tieying Zhang.;Jianjun Shen.;Ning Shang.;Jing Han.;Hui Wang.;Weiwei Kang.;Fankun Meng.
来源: BMC Gastroenterol. 2021年21卷1期395页
Patients with primary biliary cholangitis (PBC) often have comorbid dyslipidemia, and determining the degree of hepatic steatosis can help predict the risk of cardiovascular events in PBC patients. The aim of our study was to analyze the characteristics of lipid distribution and the degree of hepatic steatosis in PBC.
5576. Retraction Note to: Slug down-regulation by RNA interference inhibits invasion growth in human esophageal squamous cell carcinoma.
作者: Peng Tang.;Zhentao Yu.;Kejun Zhang.;Yu Wang.;Zhongliang Ma.;Shaoyan Zhang.;Dong Chen.;Yanbing Zhou.
来源: BMC Gastroenterol. 2021年21卷1期397页 5577. Comparison of sampling methods in assessing the microbiome from patients with ulcerative colitis.
作者: Dan Kim.;Jun-Young Jung.;Hyun-Seok Oh.;Sam-Ryong Jee.;Sung Jae Park.;Sang-Heon Lee.;Jun-Sik Yoon.;Seung Jung Yu.;In-Cheol Yoon.;Hong Sub Lee.
来源: BMC Gastroenterol. 2021年21卷1期396页
Dysbiosis of ulcerative colitis (UC) has been frequently investigated using readily accessible stool samples. However, stool samples might insufficiently represent the mucosa-associated microbiome status. We hypothesized that luminal contents including loosely adherent luminal bacteria after bowel preparation may be suitable for diagnosing the dysbiosis of UC.
5578. Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals.
作者: Kasper A Overbeek.;Michael G Goggins.;Mohamad Dbouk.;Iris J M Levink.;Brechtje D M Koopmann.;Miguel Chuidian.;Ingrid C A W Konings.;Salvatore Paiella.;Julie Earl.;Paul Fockens.;Thomas M Gress.;Margreet G E M Ausems.;Jan-Werner Poley.;Nirav C Thosani.;Elizabeth Half.;Jesse Lachter.;Elena M Stoffel.;Richard S Kwon.;Alina Stoita.;Fay Kastrinos.;Aimee L Lucas.;Sapna Syngal.;Randall E Brand.;Amitabh Chak.;Alfredo Carrato.;Frank P Vleggaar.;Detlef K Bartsch.;Jeanin E van Hooft.;Djuna L Cahen.;Marcia Irene Canto.;Marco J Bruno.; .
来源: Gastroenterology. 2022年162卷3期772-785.e4页
To successfully implement imaging-based pancreatic cancer (PC) surveillance, understanding the timeline and morphologic features of neoplastic progression is key. We aimed to investigate the progression to neoplasia from serial prediagnostic pancreatic imaging tests in high-risk individuals and identify factors associated with successful early detection.
5579. MicroRNA-15a/16-1 Prevents Hepatocellular Carcinoma by Disrupting the Communication Between Kupffer Cells and Regulatory T Cells.
作者: Ningning Liu.;Ching Wen Chang.;Clifford J Steer.;Xin Wei Wang.;Guisheng Song.
来源: Gastroenterology. 2022年162卷2期575-589页
Hepatocellular carcinoma (HCC) is characterized by intratumoral accumulation of regulatory T cells (Tregs), which suppresses antitumor immunity. This study was designed to investigate how microRNAs regulate immunosuppression in HCC.
|